FEMY

MKT CAP:$12M

Femasys Inc.

Market Cap

$12M

Healthcare·Medical - Instruments & Supplies·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$0.44-$0.20 (-31.52%)

Apr 22, 2026

Company Details

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a bi...

CEO

Kathy Lee-Sepsick

IPO Date

Jun 18, 2021

Website

www.femasys.com

Key Metrics TTM

Revenue

$2M

+63.5% YoY

Net Income

-$20M

EPS (Diluted)

-$0.71

Free Cash Flow

-$20M

Revenue / Share

$0.07

Gross Margin

42.4%

Operating Margin

-858.0%

Net Margin

-960.5%

FCF Margin

-973.8%

P/S

5.7x

P/E

—

Earnings Reports

Q4 2025

May 7, 2026

PENDING

FY 2025

Mar 31, 2026

$2M+40.8%EPS -$0.47

Q3 2025

Nov 14, 2025

$729.4K+31.4%EPS -$0.10

Q2 2025

Aug 8, 2025

$409.3K+84.8%EPS -$0.16

Q1 2025

May 8, 2025

$341.3K+25.9%EPS -$0.23

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$254.3K	$190.0K	-$2M
Q1 22	$321.4K	$198.7K	-$3M
Q2 22	$303.1K	$200.8K	-$3M
Q3 22	$347.5K	$216.0K	-$3M
Q4 22	$234.2K	$148.8K	-$3M
Q1 23	$294.0K	$188.9K	-$3M
Q2 23	$320.5K	$210.0K	-$3M
Q3 23	$244.4K	$158.2K	-$4M
Q4 23	$213.1K	$134.8K	-$4M
Q1 24	$271.1K	$182.6K	-$3M
Q2 24	$221.5K	$148.4K	-$4M
Q3 24	$554.9K	$364.1K	-$5M
Q4 24	$581.6K	$389.2K	-$5M
Q1 25	$341.3K	$224.0K	-$5M
Q2 25	$409.3K	$36.2K	-$4M
Q3 25	$729.4K	$224.5K	-$4M

Valuation

Quarter	P/S	P/E
Q4 21	39.9x	—
Q1 22	22.4x	—
Q2 22	25.3x	—
Q3 22	10.5x	—
Q4 22	11.6x	—
Q1 23	12.5x	—
Q2 23	6.2x	—
Q3 23	77.1x	—
Q4 23	18.9x	—
Q1 24	36.4x	—
Q2 24	27.4x	—
Q3 24	20.1x	—
Q4 24	15.4x	—
Q1 25	18.5x	—
Q2 25	12.9x	—
Q3 25	4.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$2M	-$2M
Q1 22	-$3M	-$3M
Q2 22	-$2M	-$3M
Q3 22	-$3M	-$3M
Q4 22	-$3M	-$3M
Q1 23	-$3M	-$3M
Q2 23	-$3M	-$3M
Q3 23	-$3M	-$3M
Q4 23	-$3M	-$3M
Q1 24	-$5M	-$5M
Q2 24	-$4M	-$5M
Q3 24	-$5M	-$6M
Q4 24	-$5M	-$5M
Q1 25	-$5M	-$5M
Q2 25	-$4M	-$4M
Q3 25	-$5M	-$6M

Capital Expenditures

Quarter	CapEx
Q4 21	$118.6K
Q1 22	$120.4K
Q2 22	$174.7K
Q3 22	$18.5K
Q4 22	$93.9K
Q1 23	$8.9K
Q2 23	$62.9K
Q3 23	$27.2K
Q4 23	$44.9K
Q1 24	$90.2K
Q2 24	$207.0K
Q3 24	$440.0K
Q4 24	$110.6K
Q1 25	$96.6K
Q2 25	$94.2K
Q3 25	$194.3K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	-9.5%	+34.3%
Q1 22	-2.5%	+48.6%
Q2 22	-7.0%	+33.0%
Q3 22	+28.9%	+35.0%
Q4 22	-7.9%	+23.8%
Q1 23	-8.5%	+4.1%
Q2 23	+5.7%	+9.9%
Q3 23	-29.7%	+27.1%
Q4 23	-9.0%	+44.1%
Q1 24	-7.8%	+11.9%
Q2 24	-30.9%	+44.4%
Q3 24	+127.1%	+31.2%
Q4 24	+172.9%	+13.8%
Q1 25	+25.9%	+55.4%
Q2 25	+84.8%	-9.4%
Q3 25	+31.4%	-22.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$29.4K	11.6%
Q1 22	$44.4K	13.8%
Q2 22	$62.2K	20.5%
Q3 22	$51.8K	14.9%
Q4 22	$66.7K	28.5%
Q1 23	$57.0K	19.4%
Q2 23	$65.2K	20.3%
Q3 23	$504.4K	206.4%
Q4 23	$49.2K	23.1%
Q1 24	$77.6K	28.6%
Q2 24	$104.0K	47.0%
Q3 24	$128.4K	23.1%
Q4 24	$134.1K	23.1%
Q1 25	$367.2K	107.6%
Q2 25	$182.0K	44.5%
Q3 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 21	$1M	$1M	$120.8K
Q1 22	$1M	$1M	$68.9K
Q2 22	$1M	$1M	$63.2K
Q3 22	$2M	$1M	$90.4K
Q4 22	$1M	$1M	$336.4K
Q1 23	$2M	$1M	$244.9K
Q2 23	$2M	$1M	$128.9K
Q3 23	$2M	$2M	$70.9K
Q4 23	$2M	$2M	$205.4K
Q1 24	$2M	$2M	$300.5K
Q2 24	$2M	$2M	$975.2K
Q3 24	$2M	$2M	$2M
Q4 24	$2M	$2M	$1M
Q1 25	$3M	$2M	$908.6K
Q2 25	$1M	$2M	$985.0K
Q3 25	$1M	$1M	$1M

Revenue by Geography

Quarter	Non-US	United States
Q2 25	$72.0K	$337.3K
Q3 25	$392.8K	$336.6K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$22M	$0	$22M
Q2 22	$19M	$0	$19M
Q3 22	$16M	$0	$16M
Q4 22	$13M	$0	$13M
Q1 23	$10M	$0	$10M
Q2 23	$11M	$0	$11M
Q3 23	$9M	$0	$9M
Q4 23	$22M	$0	$22M
Q1 24	$18M	$0	$18M
Q2 24	$14M	$0	$14M
Q3 24	$8M	$0	$8M
Q4 24	$3M	$0	$3M
Q1 25	$4M	$0	$4M
Q2 25	$3M	$0	$3M
Q3 25	$5M	$0	$5M
Q4 25	$9M	$0	$9M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	12M	+0.0%	+29.5%
Q1 22	12M	+0.0%	+0.4%
Q2 22	12M	+0.1%	+0.3%
Q3 22	12M	+0.0%	+0.1%
Q4 22	12M	-0.1%	+0.0%
Q1 23	12M	+0.6%	+0.6%
Q2 23	13M	+10.4%	+11.0%
Q3 23	15M	+15.1%	+27.8%
Q4 23	22M	+43.5%	+83.5%
Q1 24	22M	+0.5%	+83.4%
Q2 24	22M	+2.0%	+69.5%
Q3 24	22M	+0.1%	+47.3%
Q4 24	23M	+2.5%	+5.3%
Q1 25	25M	+10.3%	+15.5%
Q2 25	29M	+14.8%	+30.0%
Q3 25	29M	0.0%	+29.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$9.4K	27
Q1 22	$11.9K	27
Q2 22	$11.2K	27
Q3 22	$12.9K	27
Q4 22	$6.9K	34
Q1 23	$8.6K	34
Q2 23	$9.4K	34
Q3 23	$7.2K	34
Q4 23	$6.7K	32
Q1 24	$8.5K	32
Q2 24	$6.9K	32
Q3 24	$17.3K	32
Q4 24	$8.4K	69
Q1 25	$4.9K	69
Q2 25	$5.9K	69
Q3 25	$10.6K	69

Revenue / Employee